Journal article

The relaxin receptor as a therapeutic target - perspectives from evolution Cheek for updates and drug targeting

Ross AD Bathgate, Martina Kocan, Daniel J Scott, M Akhter Hossain, Sara V Good, Sergey Yegorov, Jan Bogerd, Paul R Gooley

Pharmacology & Therapeutics | PERGAMON-ELSEVIER SCIENCE LTD | Published : 2018

Grants

Awarded by National Health and Medical Research Council of Australia project


Awarded by Australian Research Council


Awarded by NHMRC Research Fellowship


Awarded by Norwegian Research Council BIOTEK project SALMOSTERILE


Funding Acknowledgements

Research described in this review was supported by National Health and Medical Research Council of Australia project grants [628427] and [1043750] (RADB, DJS and PRG) and [1122170] (MAH, RADB, MK) the Victorian Government Operational Infrastructure Support Program and equipment grants from the Australian Research Council [LE120100022]. RADB is supported by an NHMRC Research Fellowship [1042650]. DJS is an NHMRC Boosting Dementia Research Leadership Fellow. SVG is supported by Natural Sciences and Engineering Research Council of Canada (NSERC). JB is supported by the Norwegian Research Council BIOTEK2021 project SALMOSTERILE (221648). The authors would like to thank Daniel Ocampo Daza for the line-drawing animal illustrations used in Figs. 4 and 5.